Holen Sie sich die Stockscreener-App
0.20
11.31%
-0.0255
Schlusskurs vom Vortag:
$0.2255
Offen:
$0.28065
24-Stunden-Volumen:
170.30M
Relative Volume:
4.02
Marktkapitalisierung:
$11.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.39M
KGV:
-0.2381
EPS:
-0.84
Netto-Cashflow:
$-18.45M
1W Leistung:
+43.78%
1M Leistung:
-93.36%
6M Leistung:
-88.37%
1J Leistung:
-85.92%
1-Tages-Spanne:
$0.1911
$0.2976
1-Wochen-Bereich:
$0.1251
$0.9801
52-Wochen-Spanne:
$0.1251
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
Firmenname
Quince Therapeutics Inc
Sektor
Branche
Telefon
415-910-5717
Adresse
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
0.20 | 12.56M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Eingeleitet | Oppenheimer | Outperform |
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort - The Globe and Mail
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours - Benzinga
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Quince Therapeutics engages LifeSci Capital for strategic alternatives - marketscreener.com
Quince Therapeutics Inc (QNCX) Stock Price, Quote, News & History - Benzinga
Quince Therapeutics stock plummets after revealing strategic alternatives - Investing.com
Quince TherapeuticsOn Feb 9, Engaged Lifesci Capital For Strategic AlternativesSEC Filing - TradingView
Best Penny Stocks To Watch Now – February 10th - Defense World
Small Cap Stocks To Follow Now – February 10th - Defense World
Does Quince Therapeutics Inc. align with a passive investing strategyTrade Entry Summary & Free Weekly Watchlist of Top Performers - mfd.ru
Quince Therapeutics Stock Extends Rally On Strategic Review - Benzinga
Quince Therapeutics (QNCX) Stock Surges 300% on Strategic Alternative Plans - parameter.io
Published on: 2026-02-11 18:23:48 - mfd.ru
Quince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors Emerge - Blockonomi
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
QNCX Stock Price and Chart — NASDAQ:QNCX - TradingView
Quince Therapeutics (QNCX) Stock: What’s Behind the 300% Rally? - CoinCentral
Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive - TechStock²
Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
Why is Quince Therapeutics stock soaring Tuesday? - MSN
QNCX (Quince Therapeutics) NASDAQ intraday up 182.82% to $0.39: watch strategic-review momentum - Meyka
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Mena FN
Why Is Quince Therapeutics Stock Soaring Tuesday? - Benzinga
Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move - TechStock²
Quince Therapeutics Exploring Strategic Alternatives; Stock Soars - Nasdaq
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - PharmiWeb.com
Quince Therapeutics stock soars after engaging LifeSci Capital as advisor By Investing.com - Investing.com Australia
Quince Therapeutics stock soars after engaging LifeSci Capital as advisor - Investing.com
Fed Meeting: What is Quince Therapeutics Incs debt to equity ratio2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
Quince Therapeutics Announces Significant Board of Directors Resignations - The Globe and Mail
Quince stock plunges 95% following failed clinical trial for inherited childhood disease - The Business Journals
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure - Clinical Trials Arena
Why did QNCX stock plummet over 90% today? - MSN
Lucid Cap Mkts Downgrades Quince Therapeutics (NASDAQ:QNCX) to Strong Sell - Defense World
Quince Therapeutics (NASDAQ:QNCX) Cut to Hold at Brookline Capital Management - Defense World
Quince’s eDSP on ice after Neat phase III fails in A-T - BioWorld MedTech
Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground - Citeline News & Insights
This Codere Online Luxembourg Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
QNCX Downgraded to 'Hold' by D. Boral Capital Analyst | QNCX Sto - GuruFocus
Quince Therapeutics (QNCX) Downgraded by Citizens to Market Perf - GuruFocus
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital By Investing.com - Investing.com Nigeria
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital - Investing.com Nigeria
Lucid Capital Markets downgrades Quince Therapeutics stock to Sell after failed trial By Investing.com - Investing.com India
Lucid Capital Markets downgrades Quince Therapeutics stock to Sell after failed trial - Investing.com
Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp - MarketBeat
Quince Therapeutics (QNCX) Downgraded Following Phase 3 Trial Mi - GuruFocus
Finanzdaten der Quince Therapeutics Inc-Aktie (QNCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):